Importance of Long-Acting Injectable Antipsychotic Preparation, Administration, and Injection Site Tolerability: A Focus on Paliperidone Palmitate Once-Every-6-Months Formulation

Table 1

Baseline demographics and disease characteristics in the double-blind intention-to-treat analysis set [16].

Characteristic	PP6M, n = 478	PP3M, n = 224
Mean age (SD), years	41.2 (11.77)	40.0 (10.98)
Sex, n (%)
Male	326 (68.2)	154 (68.8)
Race, n (%)
White	353 (73.8)	168 (75.0)
Asian	66 (13.8)	30 (13.4)
Black and/or African American	49 (10.3)	23 (10.3)
Other^a	6 (1.3)	2 (0.9)
Ethnicity, n (%)
Not Hispanic or Latino	397 (83.1)	197 (87.9)
Hispanic or Latino	75 (15.7)	25 (11.2)
Unknown	6 (1.3)	2 (0.9)
Mean baseline weight (SD), kg^b	81.9 (16.86)	80.8 (17.01)
Mean baseline BMI (SD), kg/m^2b	27.9 (4.96)	27.5 (4.96)
Mean age at first diagnosis of schizophrenia (SD), years	27.7 (9.01)	27.5 (9.05)

Note. BMI, body mass index; PP3M, paliperidone palmitate once-every-3-months; PP6M, paliperidone palmitate once-every-6-months. ^aIncludes patients who self-identified as Native Hawaiian or other Pacific Islander and as multiple races. ^bBased on open-label data.